A re-evaluation of fumagillin selectivity towards endothelial cells

Anticancer Res. Sep-Oct 2001;21(5):3457-60.

Abstract

We have re-evaluated the selectivity of fumagillin against endothelial cell proliferation and compared it to the reported selectivity of its potent analog TNP-470. We showed that fumagillin does not inhibit endothelial cell proliferation in a specific manner, but on the contrary it inhibits the proliferation of other cell types at the same range of concentrations. Furthermore, the IC50 values of fumagillin for endothelial cells are two orders of magnitude higher than those values reported for TNP-470 on endothelial cells; on the contrary, the IC50 value of fumagillin for human breast cancer MDA-MB231 cells is four orders of magnitude lower than the value reported for TNP-470 on the same cell line.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells / cytology
  • 3T3 Cells / drug effects
  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Aorta / cytology
  • Aorta / drug effects
  • Cattle
  • Cell Division / drug effects
  • Cells, Cultured
  • Cyclohexanes
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Fatty Acids, Unsaturated / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Organ Specificity
  • Sesquiterpenes / pharmacology
  • Tumor Cells, Cultured

Substances

  • Angiogenesis Inhibitors
  • Cyclohexanes
  • Fatty Acids, Unsaturated
  • Sesquiterpenes
  • fumagillin
  • O-(Chloroacetylcarbamoyl)fumagillol